Bio/Pharma Business

Biogen to Acquire Reata Pharmaceuticals for $7.3 Billion

August 01, 2023

Biogen’s acquisition of Reata will grant them access to Reata’s FDA-approved treatment for Friedreich’s ataxia.

AstraZeneca and Pfizer Ink $1 Billion Rare Disease Deal

August 01, 2023

AstraZeneca, via its subsidiary Alexion Pharmaceuticals, will purchase a portfolio of preclinical rare disease gene therapies from Pfizer in a deal worth up to $1 billion.

Biovian Invests €50 Million in Manufacturing Facility in Finland

July 28, 2023

The expansion project is aimed to be completed in December 2024 and the new facility will be fully operational by 2025.

Teva Pharmaceuticals and Alvotech Expand Existing Biosimilars Partnership

July 27, 2023

Teva Pharmaceuticals and Alvotech will expand their partnership for the development and commercialization of biosimilar candidates.

Crossbow Therapeutics Debuts with $80 Million in Series A Financing to Advance Antibody Therapeutics

July 24, 2023

Newly launched Crossbow Therapeutics will work to advance a novel class of antibody therapies for treating cancers.

Bristol Myers Squibb and Evotec Extend Neuroscience Pact

July 21, 2023

Under a global license agreement, Bristol Myers Squibb and Evotec will advance the development of neurodegeneration pipeline assets.

Sandoz Spin-off Gets Green Light from Novartis Board

July 21, 2023

The proposed spin-off of Sandoz into an independent entity has been approved by Novartis’ board of directors.

Pfizer and Flagship Pioneering Enter Innovation Partnership

July 21, 2023

The partnership will see Flagship and Pfizer work to create a new pipeline of innovative medicines.

Sanofi and Scribe Therapeutics Expands Genomics Collaboration

July 21, 2023

The expanded deal, now potentially worth more than $1.2 billion, will work to develop in vivo therapies, including sickle cell disease.

Novartis Acquires DTx Pharma in Deal Worth Up to $1 Billion

July 20, 2023

Novartis’ acquisition of biotech company DTx Pharma boosts its neuroscience pipeline and expands its capabilities in RNA-based therapeutics.